Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation: Results from a Prospective Study

被引:29
作者
Remberger, Mats [1 ,2 ]
Sundberg, Berit [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Clin Immunol, SE-14186 Stockholm, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Ctr Allogene Stem Cell Transplantat, SE-14186 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
HSCT; BMT; GVHD; ATG; Rabbit-IgG; BONE-MARROW-TRANSPLANTATION; ANTI-THYMOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; LEUKEMIA; BLOOD; THYMOGLOBULIN; PROPHYLAXIS; FLUDARABINE; RISK;
D O I
10.1016/j.bbmt.2009.04.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a prospective study we determined rabbit-IgG (r-IgG) levels in serum samples before (day 0) and after (days I and 7) unrelated donor hematopoietic stem cell transplantation (HSCT). Most patients suffered from a hematologic malignancy. All patients received rabbit antithymocyte globulin (ATG) as part of the conditioning for 2-4 days (2 mg/kg/day). We found a good correlation (r = 0.34, r = 0.42 and r = 0.46) between the dose of ATG and serum r-IgG levels at all 3 time points. The cumulative incidence of acute graft-versus-host disease (aGVHD) grades II-IV in patients given the 4, 6, and 8 mg/kg ATG dose was 50%, 34%, and 15% (P = .04), respectively. In patients with r-IgG <= 70 mu g/mL (n = 54) the cumulative incidence of grades II-IV aGVHD was 33% compared with only 6% in those with r-IgG >70 mu g/mL (n = 18), P = .023. Low serum levels of r-IgG seem to be a strong predictor for aGVHD grades II-IV in patients treated with Thymoglobulin before unrelated donor HSCT Biol Blood Marrow Transplant 15: 996-999 (2009) (C) 2009 American Society for Blood and Marrow Transplantation
引用
收藏
页码:996 / 999
页数:4
相关论文
共 21 条
[1]   Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants [J].
Bacigalupo, A ;
Lamparelli, T ;
Gualandi, F ;
Bregante, S ;
Raiola, AM ;
Di Grazia, C ;
Dominietto, A ;
Bruno, B ;
Galbusera, V ;
Frassoni, F ;
Podesta, M ;
Tedone, E ;
Occhini, D ;
Van Lint, MT .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (12) :656-661
[2]   Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) [J].
Bacigalupo, A ;
Lamparelli, T ;
Bruzzi, P ;
Guidi, S ;
Alessandrino, PE ;
di Bartolomeo, P ;
Oneto, R ;
Bruno, B ;
Barbanti, M ;
Sacchi, N ;
Van Lint, MT ;
Bosi, A .
BLOOD, 2001, 98 (10) :2942-2947
[3]  
BLUME KG, 1993, BLOOD, V81, P2187
[4]   Treosulfan and fludarabine:: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation [J].
Casper, J ;
Knauf, W ;
Kiefer, T ;
Wolff, D ;
Steiner, B ;
Hammer, U ;
Wegener, R ;
Kleine, HD ;
Wilhelm, S ;
Knopp, A ;
Hartung, G ;
Dölken, G ;
Freund, M .
BLOOD, 2004, 103 (02) :725-731
[5]  
Champlin R, 1996, ACTA HAEMATOL-BASEL, V95, P157
[6]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[7]  
2-F
[8]  
HOROWITZ MM, 1990, BLOOD, V75, P555
[9]  
HOWS J, 1993, BONE MARROW TRANSPL, V12, P371
[10]   Transplant-lite:: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies [J].
Khouri, IF ;
Keating, M ;
Körbling, M ;
Przepiorka, D ;
Anderlini, P ;
O'Brien, S ;
Giralt, S ;
Ippoliti, C ;
von Wolff, B ;
Gajewski, J ;
Donato, M ;
Claxton, D ;
Ueno, N ;
Andersson, B ;
Gee, A ;
Champlin, R .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2817-2824